Journal Mobile Options
Table of Contents
Vol. 28, No. 6, 2006
Issue release date: October 2006
Dev Neurosci 2006;28:488–498

Activation, Proliferation and Commitment of Endogenous Stem/Progenitor Cells to the Oligodendrocyte Lineage by TS1 in a Rat Model of Dysmyelination

Espinosa-Jeffrey A. · Zhao P. · Awosika W. · Wu N. · Macias F. · Cepeda C. · Levine M. · de Vellis J.
Mental Retardation Research Center, Semel Institute for Neuroscience and Human Behavior and Departments of Neurobiology and Psychiatry, University of California, Los Angeles, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Wild-type and myelin-deficient rats received a single intraparenchymal injection of TS1, a specific combination of IGF-1 and transferrin (Tf), into their corpus callosum at postnatal day 4. The fate of endogenous stem cells in the brain was examined by the expression of the stem cell marker nestin, together with Tf, neurofilaments and glial fibrillary acidic protein from 2 to 14 days after injection. Treated mutants lacked nestin expression in the ventricular wall and had an increase in nestin-labeled radial cell processes in the subventricular regions, and extended into the parenchyma. The subventricular zone was populated by healthy new oligodendrocytes (OLs). BrdU incorporation showed that these cells originated by proliferation and were identified as OLs based upon Tf expression. Thus, TS1 is an effective treatment to promote endogenous subventricular zone progenitor proliferation, migration and OL lineage specification. This strategy offers for the first time the possibility of myelin restoration to treat myelin disorders.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Rubenstein JL, Shimamura K, Martinez S, Puelles L: Regionalization of the prosencephalic neural plate. Annu Rev Neurosci 1998;21:445–477.
  2. Fraichard A, Chassande O, Bilbaut G, Dehay C, Savatier P, Samarut J: In vitro differentiation of embryonic stem cells into glial cells and functional neurons. J Cell Sci 1995;108:3181–3188.
  3. Lendahl U, Zimmerman L, McKay R: CNS stem cells express a new class of intermediate filament protein. Cell 1990;60:585–595.
  4. Messam C, Hou E, Major E: Coexpression of nestin in neural and glial cells in the developing human CNS defined by a human specific anti-nestin antibody. Exp Neurol 2000;161:585–596.
  5. Espinosa de los Monteros A, Chiappelli F, Fisher RS, de Vellis J: Transferrin: an early marker of oligodendrocytes in culture. Int J Dev Neurosci 1988;6:167–175.
  6. Pfeiffer S, Warrington A, Bansal R: The oligodendrocyte and its many cellular processes. Trends Cell Biol 1993;3:191–197.
  7. Kumar S, Gordon MN, Espinosa de los Monteros MA, de Vellis J: Developmental expression of neural cell type-specific mRNA markers in the myelin-deficient mutant rat brain: inhibition of oligodendrocyte differentiation. J Neurosci Res 1988;21:268–274.
  8. Kumar S, Macklin WB, Gordon MN, Espinosa de los Monteros A, Cole R, Scully SA, de Vellis J: Transcriptional regulation studies of myelin-associated genes in myelin-deficient mutant rats. Dev Neurosci 1990;12:316–325.
  9. Gordon M, Kumar S, Espinosa de los Montero A, de Vellis J: Ontogeny of glycerol phosphate dehydrogenase-positive oligodendrocytes in rat brain impaired differentiation of oligodendrocytes in the myelin deficient mutant rat. Int J Dev Neurosci 1992;10:243–253.
  10. Espinosa de los Monteros A, Zhang M, Gordon MN, Kumar S, Scully S, de Vellis J: The myelin-deficient rat mutant: partial recovery of oligodendrocyte maturation in vitro. Dev Neurosci 1990;12:326–333.
  11. Yamaguchi M, Saito H, Suzuki M, Mori K: Visualization of neurogenesis in the central nervous system using nestin promoter-GFP transgenic mice. Neuroreport 2002;11:1991–1996.
  12. Espinosa de los Monteros A, Kumar S, Zhao P, Huang CJ, Nazarian R, Pan T, Scully S, Chang R, de Vellis J: Transferrin is an essential factor for myelination. Neurochem Res 1999;24:235–248.
  13. Espinosa-Jeffrey A, Kumar S, Zhao PM, Awosika O, Agbo C, Huang A, Chang R, de Vellis J: Transferrin regulates transcription of the MBP gene and its action synergizes with IGF-1 to enhance myelinogenesis in the md rat. Dev Neurosci 2002;24:227–241.
  14. Cepeda C, Colwell CS, Itri JN, Chandler SH, Levine MS: Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J Neurophysiol 1998;79:82–94.
  15. Bansal R, Miyake H, Nakamura I, Eto H, Gotoh A, Fujisawa M, Okada H, Arakawa SR, Kamidono S, Hara I: Fibroblast growth factors and their receptors in oligodendrocyte development: implications for demyelination and remyelination. Dev Neurosci 2002;24:35–46.
  16. McMorris FA, Dubois-Dalcq M: Insulin-like growth factor I promotes cell proliferation and oligodendroglial commitment in rat glial progenitor cells developing in vitro. J Neurosci Res 1988;21:199–209.
  17. McMorris FA, Furlanetto RW, Mozell RL, Carson MJ, Raible DW: Regulation of oligodendrocyte development by insulin-like growth factors and cyclic nucleotides. Ann NY Acad Sci 1990;605:101–109.
  18. McMorris FA, McKinnon RD: Regulation of oligodendrocyte development and CNS myelination by growth factors: prospects for therapy of demyelinating disease. Brain Pathol 1996;6:313–329.
  19. Bartlett WP, Li XS, Williams M: Expression of IGF-1 mRNA in the murine subventricular zone during postnatal development. Brain Res Mol Brain Res 1992;12:285–291.
  20. Araujo DM, Lapchak PA, Collier P, Chabot JG, Qirion R: Insulin-like growth factor-1 (somatomedin-C) receptors in the rat brain: distribution and interaction with the hippocampal cholinergic system. Brain Res 1989;484:130–138.
  21. Werner H, Roberts Jr, CT, LeRoith D: The regulation of IGF-I receptor gene expression by positive and negative zinc-finger transcription factors. Adv Exp Med Biol 1993;343:91–103.
  22. Kar S, Chabot JG, Quirion R: Quantitative autoradiographic localization of [125I]insulin-like growth factor I, [125I]insulin-like growth factor II, and [125I]insulin receptor binding sites in developing and adult rat brain. J Comp Neurol 1993;333:375–397.
  23. Sara V, Hall K: Insulin-like growth factors and their binding proteins. Physiol Rev 1990;70:591–614.
  24. Mason JL, Jones JJ, Taniike M, Suzuki K, Morell P, Matsushima GK: Mature oligodendrocyte apoptosis precedes IGF-1 production and oligodendrocyte progenitor accumulation and differentiation during demyelination/remyelination. J Neurosci Res 2000;61:251–262.
  25. Baron-Van Evercooren A, Avellana-Adalid V, Ben Younes-Chennoufi A, Gansmuller A, Nait-Oumesmar B, Vignais L: Cell-cell interactions during the migration of myelin-forming cells transplanted in the demyelinated spinal cord. Glia 1996;16:147–164.
  26. Ellison J, de Vellis J: Platelet-Derived growth factor receptor is expressed by cells in the early oligodendrocyte lineage. J Neurosci Res 1994;37:116–128.
  27. Barres BR, Schmid R, Sendnter M, Raff M: Multiple extracellular signals are required for longterm oligodendrocyte survival. Development 1993;118:283–295.
  28. Wei L, Shi M, Chen L, Cao R, Zhang P, Chan Y: Nestin-containing cells express glial fibrillary acidic protein in the proliferative regions of central nervous system of postnatal developing and adult mice. Dev Brain Res 2002;139:9–17.
  29. Hsieh J, Aimone J, Kaspar B, Kuwabara T, Nakashima K, Gage F: IGF-1 instructs multipotent neural progenitor cells to become oligodendrocytes. J Cell Biol 2004;164:111–122.

Pay-per-View Options
Direct payment This item at the regular price: USD 9.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 8.00